CN103601666B - The preparation method of octahydro pentamethylene [C] pyrroles - Google Patents
The preparation method of octahydro pentamethylene [C] pyrroles Download PDFInfo
- Publication number
- CN103601666B CN103601666B CN201310627653.8A CN201310627653A CN103601666B CN 103601666 B CN103601666 B CN 103601666B CN 201310627653 A CN201310627653 A CN 201310627653A CN 103601666 B CN103601666 B CN 103601666B
- Authority
- CN
- China
- Prior art keywords
- preparation technology
- tetrahydrofuran
- reaction substrate
- pyrroles
- reductive agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 title claims abstract 5
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 title claims abstract 5
- 150000003233 pyrroles Chemical class 0.000 title claims abstract 5
- 230000002829 reductive effect Effects 0.000 claims abstract description 11
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229910052796 boron Inorganic materials 0.000 claims abstract description 4
- 239000003795 chemical substances by application Substances 0.000 claims abstract 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 42
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 21
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 21
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 12
- 239000000758 substrate Substances 0.000 claims description 8
- 239000011592 zinc chloride Substances 0.000 claims description 8
- 235000005074 zinc chloride Nutrition 0.000 claims description 8
- 238000005516 engineering process Methods 0.000 claims description 7
- 239000012046 mixed solvent Substances 0.000 claims description 7
- 239000012279 sodium borohydride Substances 0.000 claims description 7
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- -1 valeryl imines Chemical class 0.000 claims description 6
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 5
- 239000011591 potassium Substances 0.000 claims description 5
- 229910052700 potassium Inorganic materials 0.000 claims description 5
- 238000009835 boiling Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 10
- 239000002841 Lewis acid Substances 0.000 abstract description 5
- 150000007517 lewis acids Chemical class 0.000 abstract description 5
- 230000009467 reduction Effects 0.000 abstract description 2
- 125000000879 imine group Chemical group 0.000 abstract 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 36
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- 239000012074 organic phase Substances 0.000 description 15
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 239000003638 chemical reducing agent Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 229910010082 LiAlH Inorganic materials 0.000 description 6
- UZHVXJZEHGSWQV-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydrocyclopenta[c]pyrrole Chemical compound C1NCC2CCCC21 UZHVXJZEHGSWQV-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000009776 industrial production Methods 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- 239000012299 nitrogen atmosphere Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012450 pharmaceutical intermediate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 229960002935 telaprevir Drugs 0.000 description 2
- BBAWEDCPNXPBQM-GDEBMMAJSA-N telaprevir Chemical compound N([C@H](C(=O)N[C@H](C(=O)N1C[C@@H]2CCC[C@@H]2[C@H]1C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1)C(C)(C)C)C1CCCCC1)C(=O)C1=CN=CC=N1 BBAWEDCPNXPBQM-GDEBMMAJSA-N 0.000 description 2
- 108010017101 telaprevir Proteins 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- QCWDCTDYSDJKTP-UHFFFAOYSA-N O=C(C1C2CCC1)NC2=O Chemical compound O=C(C1C2CCC1)NC2=O QCWDCTDYSDJKTP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000517 boceprevir Drugs 0.000 description 1
- LHHCSNFAOIFYRV-DOVBMPENSA-N boceprevir Chemical compound O=C([C@@H]1[C@@H]2[C@@H](C2(C)C)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)NC(C(=O)C(N)=O)CC1CCC1 LHHCSNFAOIFYRV-DOVBMPENSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 229960002089 ferrous chloride Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
技术领域technical field
本发明属于化学制药领域,具体地涉及药物关键合成中间体八氢环戊烷[C]吡咯(octahydrocyclopenta[c]pyrrole,CAS No.为5661-03-0)的制备方法。The invention belongs to the field of chemical pharmacy, and in particular relates to a preparation method of octahydrocyclopenta[c]pyrrole (octahydrocyclopenta[c]pyrrole, CAS No. 5661-03-0), a key synthetic intermediate of medicine.
背景技术Background technique
丙型肝炎病毒是一种单股线性正链RNA病毒,由于会导致各种慢性肝病发生,丙型肝炎病毒是迄今为止人类因疾病而死亡的主要杀手之一。2011年美国食品药品管理局(FDA)批准了特拉匹韦(Telaprevir)和伯赛匹韦(Boceprevir)两个小分子药物在美国上市。这两个蛋白酶抑制剂的上市,改变了以往十多年来丙肝的治疗效果;这在丙肝治疗领域是比较大的突破。Hepatitis C virus is a single-stranded linear positive-sense RNA virus. Because it can cause various chronic liver diseases, HCV is one of the main killers of human deaths due to diseases so far. In 2011, the U.S. Food and Drug Administration (FDA) approved two small-molecule drugs, Telaprevir and Boceprevir, to be marketed in the United States. The launch of these two protease inhibitors has changed the treatment effect of hepatitis C in the past ten years; this is a relatively big breakthrough in the field of hepatitis C treatment.
八氢环戊烷[C]吡咯(或其盐)是一种在药物合成中非常有用的医药中间体。它不仅是合成特拉匹韦(Telaprevir)的关键中间体,而且还是糖尿病药物格列齐特(gliclazide)的合成中间体。因此,对于它的大规模工业化生产,具有非常重要的市场价值。八氢环戊烷[C]吡咯为以下结构式(I):Octahydrocyclopentane[C]pyrrole (or its salt) is a very useful pharmaceutical intermediate in drug synthesis. It is not only a key intermediate for the synthesis of telaprevir, but also a synthetic intermediate for the diabetes drug gliclazide. Therefore, for its large-scale industrial production, it has very important market value. Octahydrocyclopentane [C] pyrrole is the following structural formula (I):
八氢环戊烷[C]吡咯的制备方法很早就有文献报道:R.Griot于1959年在Helv.Chim.Acta.,1959,67-72杂志上首次提出了一条直接的合成方法;Griot采用LiAlH4在四氢呋喃溶液中还原环戊酰亚胺(II),以51%收率得到目标化合物八氢环戊烷[C]吡咯(I)。The preparation method of octahydrocyclopentane [C] pyrrole has been reported in the literature for a long time: R.Griot first proposed a direct synthetic method in Helv.Chim.Acta., 1959,67-72 magazine in 1959; Griot The target compound octahydrocyclopentane[C]pyrrole (I) was obtained by reducing cyclopentanimide (II) in tetrahydrofuran solution with LiAlH 4 in 51% yield.
WO2009/55467报道了另一条合成方法:N-苄基环戊酰亚胺先经LiAlH4还原后,再使用10%钯碳(Pd/C)加氢还原以55%的总收率两步得到目标化合物八氢环戊烷[C]吡咯(I)。该方法流程如下:WO2009/55467 reported another synthetic method: N-benzyl cyclopentanimide was first reduced by LiAlH 4 and then hydrogenated with 10% palladium on carbon (Pd/C) to obtain it in two steps with a total yield of 55%. The target compound octahydrocyclopentane[C]pyrrole (I). The method flow is as follows:
在对八氢环戊烷[C]吡咯的药物中间体的工业化研发中,发明人发现以上两种方法一方面得到最终产品的收率都不高,低于55%;此外还均需要使用大量的氢化铝锂(LiAlH4),而LiAlH4是一种遇水非常敏感的化学试剂,实验室在应用时,因为使用量小,危险度还能够容忍;然而在工业化生产中,由于使用量大,其危险性非常大,在还原反应过程中以及后处理过量的还原剂LiAlH4时会剧烈放热,在局部热不均匀的情况下,非常容易发生爆炸等安全事故。一般而言,化学工业化生产中,应该避免使用如LiAlH4这样的遇水非常敏感的化学试剂。In the industrial research and development of the pharmaceutical intermediates of octahydrocyclopentane [C] pyrrole, the inventor found that the yield of the final product obtained by the above two methods on the one hand is not high, lower than 55%; Lithium aluminum hydride (LiAlH 4 ), and LiAlH 4 is a chemical reagent that is very sensitive to water. In laboratory applications, because the amount of use is small, the risk can be tolerated; however, in industrial production, due to the large amount of use , its danger is very high, during the reduction reaction process and after treatment of excess reducing agent LiAlH 4 will violently exothermic, in the case of local heat inhomogeneity, it is very easy to cause safety accidents such as explosion. Generally speaking, chemical reagents that are very sensitive to water such as LiAlH 4 should be avoided in chemical industrial production.
迄今为止,还没有报道八氢环戊烷[C]吡咯的工业化生产方法,迫切需要找到一种安全且高收率的有效工业量化生产方法。So far, no industrial production method of octahydrocyclopentane[C]pyrrole has been reported, and it is urgent to find a safe and effective industrial quantitative production method with high yield.
发明内容Contents of the invention
本发明的目的是提供一种符合工业化生产的八氢环戊烷[C]吡咯(I)的制备方法。The object of the present invention is to provide a kind of preparation method of octahydrocyclopentane [C] pyrrole (I) that is suitable for industrialized production.
为实现上述目的,本发明在深入研究后,设计了制备八氢环戊烷[C]吡咯新的不同于现有技术的方法,即由环戊酰亚胺(II)在适当还原剂及适当促进剂作用下通过“一步法”直接还原得到目标化合物八氢环戊烷[C]吡咯(I)。In order to achieve the above object, after in-depth research, the present invention has designed a new method different from the prior art for preparing octahydrocyclopentane [C] pyrrole, that is, by cyclopentanimide (II) in a suitable reducing agent and a suitable The target compound octahydrocyclopentane[C]pyrrole (I) was obtained by direct reduction under the action of a promoter in a "one-step method".
具体地说,本发明提供的八氢环戊烷[C]吡咯(I)的制备方法,包括将反应底物环戊酰亚胺(II)在硼还原剂以及路易斯酸促进剂作用下,在适当溶剂中,在适当温度下反应,得到目标化合物八氢环戊烷[C]吡咯(I)。Specifically, the preparation method of octahydrocyclopentane [C] pyrrole (I) provided by the present invention comprises the reaction substrate cyclopentanimide (II) under the action of a boron reducing agent and a Lewis acid promoter, in In a suitable solvent, react at a suitable temperature to obtain the target compound octahydrocyclopentane[C]pyrrole (I).
一种实施方式中,所述适当还原剂选自硼氢化钠或硼氢化钾;优选硼氢化钠。In one embodiment, the suitable reducing agent is selected from sodium borohydride or potassium borohydride; preferably sodium borohydride.
一种实施方式中,所述路易斯酸促进剂选自氯化锌、氯化钙、氯化铁、氯化亚铁、氯化镁等;更优选地,所述路易斯酸促进剂为氯化锌。In one embodiment, the Lewis acid accelerator is selected from zinc chloride, calcium chloride, ferric chloride, ferrous chloride, magnesium chloride, etc.; more preferably, the Lewis acid accelerator is zinc chloride.
一种实施方式中,所述适当溶剂为惰性溶剂;所述惰性溶剂选自四氢呋喃、乙腈、1,4-二氧六环、甲苯、二甲苯、苯、乙二醇二甲醚、乙二醇单甲醚、N,N-二甲基甲酰胺、二甲亚砜、氯仿单一溶剂或其中两种或两种以上的混合溶剂。优选地,溶剂为四氢呋喃或甲苯,或两者的混合溶剂。In one embodiment, the appropriate solvent is an inert solvent; the inert solvent is selected from tetrahydrofuran, acetonitrile, 1,4-dioxane, toluene, xylene, benzene, ethylene glycol dimethyl ether, ethylene glycol Monomethyl ether, N,N-dimethylformamide, dimethyl sulfoxide, chloroform as a single solvent or a mixed solvent of two or more of them. Preferably, the solvent is tetrahydrofuran or toluene, or a mixed solvent of the two.
一种实施方式中,反应使用单一溶剂,反应温度为所用溶剂的回流温度。In one embodiment, the reaction uses a single solvent, and the reaction temperature is the reflux temperature of the solvent used.
一种实施方式中,反应使用混合溶剂,反应温度为所用各溶剂的沸点之间的任意温度或是该混合溶剂的共沸温度。In one embodiment, a mixed solvent is used for the reaction, and the reaction temperature is any temperature between the boiling points of the solvents used or the azeotropic temperature of the mixed solvent.
一种实施方式中,所述还原剂与反应底物(II)的摩尔比为1:1至10:1;优选1.1:1至5:1。In one embodiment, the molar ratio of the reducing agent to the reaction substrate (II) is 1:1 to 10:1; preferably 1.1:1 to 5:1.
一种实施方式中,所述促进剂与反应底物(II)的摩尔比为0.5:1至10:1;优选1.1:1至5:1。In one embodiment, the molar ratio of the accelerator to the reaction substrate (II) is 0.5:1 to 10:1; preferably 1.1:1 to 5:1.
与目前已公开的技术相比,本发明的制备新方法通过还原环戊酰亚胺化合物(II),一步法制备八氢环戊烷[C]吡咯(I),优点在于,一方面采用了价格便宜,而且反应温和、操作安全的还原试剂,另一方面通过适当的路易斯酸提升了还原试剂的反应活性,产品收率较高且纯度也高(>97%)。因此该新方法采用的试剂安全、反应条件温和、产物收率高;能很好地符合工业化生产。Compared with the currently disclosed technology, the new preparation method of the present invention prepares octahydrocyclopentane [C] pyrrole (I) in one step by reducing the cyclopentanimide compound (II). The advantage is that, on the one hand, it adopts The reducing agent is cheap, mild in reaction, and safe in operation. On the other hand, the reactivity of the reducing agent is improved by an appropriate Lewis acid, and the product yield is high and the purity is also high (>97%). Therefore, the reagents used in the new method are safe, the reaction conditions are mild, and the product yield is high; it can well meet industrial production.
以下实施例仅仅是进一步阐明本发明,并无将本发明局限于该具体实施例的意图。本领域技术人员应该认识到,本发明涵盖了权利要求书范围内所有可能的备选方案、改进方案和等效方案。The following examples are only to further illustrate the present invention, and are not intended to limit the present invention to the specific examples. Those skilled in the art will realize that the invention covers all possible alternatives, modifications and equivalents within the scope of the claims.
实施例Example
原料及试剂:Raw materials and reagents:
环戊酰亚胺(II)(自制,按照现有文献由1,2-环戊二甲酸与尿脱水缩合而成);Cyclopentanimide (II) (self-made, formed by dehydration and condensation of 1,2-cyclopentadicarboxylic acid and urine according to existing literature);
硼氢化钠、硼氢化钾、氯化锌、氯化铁及其它使用的溶剂及试剂均为国药集团化学试剂有限公司提供。Sodium borohydride, potassium borohydride, zinc chloride, ferric chloride and other solvents and reagents used were provided by Sinopharm Chemical Reagent Co., Ltd.
实施例1Example 1
在氮气氛围下,往一装有机械搅拌器的5L的三口瓶中依次加入四氢呋喃(500mL)、甲苯(1.5L)、硼氢化钠(68.40g,2.5eq.)和氯化锌(125.0g,1.3eq.)。所得悬浮物加热至回流。缓慢蒸出四氢呋喃,使温度控制在90±5℃,直至有黑色固体生成。滴加环戊酰亚胺(100g,0.72mol)的四氢呋喃(500mL)溶液,并在此温度下回流过夜。冷却,用稀盐酸中和至pH=2-3,分去有机相,水相用乙酸乙酯(1L x3)萃取三次,分去有机相。带酸性的水层用碳酸钠饱和溶液中和至pH=8-9后,用乙酸乙酯(1L x3)提取。合并的有机相用硫酸镁干燥。过滤后,滤液减压浓缩。得到白色固体八氢环戊烷[C]吡咯(72.8g,90.9%),HPLC纯度为97%。Under nitrogen atmosphere, tetrahydrofuran (500mL), toluene (1.5L), sodium borohydride (68.40g, 2.5eq.) and zinc chloride (125.0g, 1.3eq.). The resulting suspension was heated to reflux. The tetrahydrofuran was distilled off slowly, and the temperature was controlled at 90±5°C until a black solid was formed. A solution of cyclopentanimide (100 g, 0.72 mol) in tetrahydrofuran (500 mL) was added dropwise and refluxed at this temperature overnight. Cool, neutralize with dilute hydrochloric acid to pH=2-3, separate the organic phase, extract the aqueous phase with ethyl acetate (1L x3) three times, and separate the organic phase. The acidic aqueous layer was neutralized to pH=8-9 with saturated sodium carbonate solution, and then extracted with ethyl acetate (1L x3). The combined organic phases were dried over magnesium sulfate. After filtration, the filtrate was concentrated under reduced pressure. Octahydrocyclopentane[C]pyrrole (72.8 g, 90.9%) was obtained as a white solid with an HPLC purity of 97%.
实施例2Example 2
在氮气氛围下,往一装有机械搅拌器的500mL的三口瓶中依次加入四氢呋喃(50mL)、甲苯(150mL)、硼氢化钠(6.84g,2.5eq.)和氯化锌(12.5g,1.3eq.)。所得悬浮物加热至回流。缓慢蒸出四氢呋喃,使温度控制在90±5℃,直至有黑色固体生成。滴加环戊酰亚胺(10g,72mmol)的四氢呋喃(50mL)溶液,并在此温度下回流过夜。冷却,用稀盐酸中和至pH=2-3,分去有机相,水相用乙酸乙酯(100mL x3)萃取三次,分去有机相。带酸性的水层用碳酸钠饱和溶液中和至pH=8-9后,用乙酸乙酯(100mL x3)提取。合并的有机相用硫酸镁干燥。过滤后,滤液减压浓缩。得到白色固体八氢环戊烷[C]吡咯(7.35g,91.8%),HPLC纯度为97%。Under nitrogen atmosphere, tetrahydrofuran (50mL), toluene (150mL), sodium borohydride (6.84g, 2.5eq.) and zinc chloride (12.5g, 1.3 eq.). The resulting suspension was heated to reflux. The tetrahydrofuran was distilled off slowly, and the temperature was controlled at 90±5°C until a black solid was formed. A solution of cyclopentanimide (10 g, 72 mmol) in tetrahydrofuran (50 mL) was added dropwise and refluxed at this temperature overnight. Cool, neutralize with dilute hydrochloric acid to pH=2-3, separate the organic phase, extract the aqueous phase with ethyl acetate (100mL x 3) three times, and separate the organic phase. The acidic aqueous layer was neutralized to pH=8-9 with saturated sodium carbonate solution, and then extracted with ethyl acetate (100mL x3). The combined organic phases were dried over magnesium sulfate. After filtration, the filtrate was concentrated under reduced pressure. Octahydrocyclopentane[C]pyrrole (7.35 g, 91.8%) was obtained as a white solid with an HPLC purity of 97%.
实施例3Example 3
在氮气氛围下,往一装有机械搅拌器的500mL的三口瓶中依次加入四氢呋喃(50mL)、甲苯(150mL)、硼氢化钾(9.76g,2.5eq.)和氯化锌(14.4g,1.5eq.)。所得悬浮物加热至回流。缓慢蒸出四氢呋喃,使温度控制在90±5℃,直至有黑色固体生成。滴加环戊酰亚胺(10g,72mmol)的四氢呋喃(50mL)溶液,并在此温度下回流过夜。冷却,用稀盐酸中和至pH=2-3,分去有机相,水相用乙酸乙酯(100mL x3)萃取三次,分去有机相。带酸性的水层用碳酸钠饱和溶液中和至pH=8-9后,用乙酸乙酯(100mL x3)提取。合并的有机相用硫酸镁干燥。过滤后,滤液减压浓缩。得到白色固体八氢环戊烷[C]吡咯(7.33g,91.6%),HPLC纯度为97%。Under nitrogen atmosphere, tetrahydrofuran (50mL), toluene (150mL), potassium borohydride (9.76g, 2.5eq.) and zinc chloride (14.4g, 1.5 eq.). The resulting suspension was heated to reflux. The tetrahydrofuran was distilled off slowly, and the temperature was controlled at 90±5°C until a black solid was formed. A solution of cyclopentanimide (10 g, 72 mmol) in tetrahydrofuran (50 mL) was added dropwise and refluxed at this temperature overnight. Cool, neutralize with dilute hydrochloric acid to pH=2-3, separate the organic phase, extract the aqueous phase with ethyl acetate (100mL x 3) three times, and separate the organic phase. The acidic aqueous layer was neutralized to pH=8-9 with saturated sodium carbonate solution, and then extracted with ethyl acetate (100mL x3). The combined organic phases were dried over magnesium sulfate. After filtration, the filtrate was concentrated under reduced pressure. Octahydrocyclopentane[C]pyrrole (7.33 g, 91.6%) was obtained as a white solid with an HPLC purity of 97%.
实施例4Example 4
在氮气氛围下,往一装有机械搅拌器的250mL的三口瓶中依次加入乙腈(25mL)、二甲苯(75mL)、硼氢化钠(4.93g,3.0eq.)和氯化铁(11.5g,2.0eq.)。所得悬浮物加热至90±5。缓慢蒸出四氢呋喃,使温度控制在90±5℃,直至有黑色固体生成。滴加环戊酰亚胺(5g,36mmol)的四氢呋喃(50mL)溶液,并在此温度下过夜。冷却,用稀盐酸中和至pH=2-3,分去有机相,水相用乙酸乙酯(100mL x3)萃取三次,分去有机相。带酸性的水层用碳酸钠饱和溶液中和至pH=8-9后,用乙酸乙酯(100mL x3)提取。合并的有机相用硫酸镁干燥。过滤后,滤液减压浓缩。得到白色固体八氢环戊烷[C]吡咯(3.26g,81.4%),HPLC纯度为95%。Under nitrogen atmosphere, acetonitrile (25mL), xylene (75mL), sodium borohydride (4.93g, 3.0eq.) and ferric chloride (11.5g, 2.0eq.). The resulting suspension was heated to 90±5. The tetrahydrofuran was distilled off slowly, and the temperature was controlled at 90±5°C until a black solid was formed. A solution of cyclopentimide (5 g, 36 mmol) in tetrahydrofuran (50 mL) was added dropwise and left at this temperature overnight. Cool, neutralize with dilute hydrochloric acid to pH=2-3, separate the organic phase, extract the aqueous phase with ethyl acetate (100mL x 3) three times, and separate the organic phase. The acidic aqueous layer was neutralized to pH=8-9 with saturated sodium carbonate solution, and then extracted with ethyl acetate (100mL x3). The combined organic phases were dried over magnesium sulfate. After filtration, the filtrate was concentrated under reduced pressure. Octahydrocyclopentane[C]pyrrole (3.26 g, 81.4%) was obtained as a white solid with 95% purity by HPLC.
实施例5Example 5
在氮气氛围下,往一装有机械搅拌器的250mL的三口瓶中依次加入四氢呋喃(25mL)、二甲苯(75mL)、硼氢化钾(11.22g,5.0eq.)和氯化锌(19.32g,4.0eq.)。所得悬浮物加热至90±5℃。缓慢蒸出四氢呋喃,使温度控制在90±5℃,直至有黑色固体生成。滴加环戊酰亚胺(5g,36mmol)的四氢呋喃(50mL)溶液,并在此温度下过夜。冷却,用稀盐酸中和至pH=2-3,分去有机相,水相用乙酸乙酯(50mL x3)萃取三次,分去有机相。带酸性的水层用碳酸钠饱和溶液中和至pH=8-9后,用乙酸乙酯(50mL x3)提取。合并的有机相用硫酸镁干燥。过滤后,滤液减压浓缩。得到白色固体八氢环戊烷[C]吡咯(3.65g,91.2%),HPLC纯度为96%。Under nitrogen atmosphere, tetrahydrofuran (25mL), xylene (75mL), potassium borohydride (11.22g, 5.0eq.) and zinc chloride (19.32g, 4.0eq.). The resulting suspension was heated to 90±5°C. The tetrahydrofuran was distilled off slowly, and the temperature was controlled at 90±5°C until a black solid was formed. A solution of cyclopentimide (5 g, 36 mmol) in tetrahydrofuran (50 mL) was added dropwise and left at this temperature overnight. Cool, neutralize with dilute hydrochloric acid to pH=2-3, separate the organic phase, extract the aqueous phase with ethyl acetate (50mL x3) three times, and separate the organic phase. The acidic aqueous layer was neutralized to pH=8-9 with saturated sodium carbonate solution, and then extracted with ethyl acetate (50mL x3). The combined organic phases were dried over magnesium sulfate. After filtration, the filtrate was concentrated under reduced pressure. Octahydrocyclopentane[C]pyrrole (3.65 g, 91.2%) was obtained as a white solid with an HPLC purity of 96%.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310627653.8A CN103601666B (en) | 2013-11-28 | 2013-11-28 | The preparation method of octahydro pentamethylene [C] pyrroles |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310627653.8A CN103601666B (en) | 2013-11-28 | 2013-11-28 | The preparation method of octahydro pentamethylene [C] pyrroles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103601666A CN103601666A (en) | 2014-02-26 |
| CN103601666B true CN103601666B (en) | 2015-09-02 |
Family
ID=50119950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310627653.8A Expired - Fee Related CN103601666B (en) | 2013-11-28 | 2013-11-28 | The preparation method of octahydro pentamethylene [C] pyrroles |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103601666B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109206357A (en) * | 2017-07-04 | 2019-01-15 | 浙江九洲药业股份有限公司 | A kind of general formula compound and its preparation method and application of gliclazide intermediate |
| CN109438325A (en) * | 2018-12-05 | 2019-03-08 | 兰州大学 | A kind of method of ring valeryl imines catalytic hydrogenation synthesis octahydro pentamethylene [C] pyrroles |
| CN116283719B (en) * | 2023-03-28 | 2023-09-08 | 安徽金鼎医药股份有限公司 | Preparation process and preparation system of gliclazide intermediate amino heterocyclic hydrochloride |
| CN117510394A (en) * | 2023-11-08 | 2024-02-06 | 内蒙古源宏精细化工有限公司 | Preparation method of N-amino-3-azabicyclo [3, 0] octane hydrochloride |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101235011A (en) * | 2008-03-11 | 2008-08-06 | 浙江大学 | N-amino-1,2-cyclopentane dicarboximide and its preparation method |
| CN101381338A (en) * | 2007-09-03 | 2009-03-11 | 上海医药工业研究院 | The preparation method of cis-perhydroisoindole |
| WO2009140279A2 (en) * | 2008-05-12 | 2009-11-19 | Concert Pharmaceuticals, Inc. | Sulfonyl urea compounds |
| CN102816102A (en) * | 2011-06-08 | 2012-12-12 | 瑟维尔实验室 | Synthesis process, and crystalline form of 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1H)-yl]propoxy} benzamide hydrochloride and pharmaceutical compositions containing it |
| CN102924362A (en) * | 2012-10-26 | 2013-02-13 | 浙江工业大学 | Preparation method of hexahydro-2-cyclopentyl-pyrryl amine hydrochloride |
| WO2013050301A1 (en) * | 2011-10-03 | 2013-04-11 | Syngenta Participations Ag | Enantionselective processes to insecticidal 3-aryl-3-trifluoromethyl-substituted pyrrolidines |
| TW201341358A (en) * | 2012-01-06 | 2013-10-16 | Lonza Ag | Method for preparation of octahydrocyclopenta[c] pyrrole |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004131399A (en) * | 2002-10-08 | 2004-04-30 | Ihara Chem Ind Co Ltd | Method for producing cis-hexahydroisoindoline |
-
2013
- 2013-11-28 CN CN201310627653.8A patent/CN103601666B/en not_active Expired - Fee Related
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101381338A (en) * | 2007-09-03 | 2009-03-11 | 上海医药工业研究院 | The preparation method of cis-perhydroisoindole |
| CN101235011A (en) * | 2008-03-11 | 2008-08-06 | 浙江大学 | N-amino-1,2-cyclopentane dicarboximide and its preparation method |
| WO2009140279A2 (en) * | 2008-05-12 | 2009-11-19 | Concert Pharmaceuticals, Inc. | Sulfonyl urea compounds |
| CN102816102A (en) * | 2011-06-08 | 2012-12-12 | 瑟维尔实验室 | Synthesis process, and crystalline form of 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1H)-yl]propoxy} benzamide hydrochloride and pharmaceutical compositions containing it |
| WO2013050301A1 (en) * | 2011-10-03 | 2013-04-11 | Syngenta Participations Ag | Enantionselective processes to insecticidal 3-aryl-3-trifluoromethyl-substituted pyrrolidines |
| TW201341358A (en) * | 2012-01-06 | 2013-10-16 | Lonza Ag | Method for preparation of octahydrocyclopenta[c] pyrrole |
| CN102924362A (en) * | 2012-10-26 | 2013-02-13 | 浙江工业大学 | Preparation method of hexahydro-2-cyclopentyl-pyrryl amine hydrochloride |
Non-Patent Citations (2)
| Title |
|---|
| A practical and efficient procedure for reduction of carboxylic acids and their derivatives: use of KBH4–MgCl2;You-Chun Qiu,等;《Tetrahedron Letters》;20070904;第48卷(第43期);第7595-7598页 * |
| 硼氢化钠在有机合成中的新应用;车荣睿;《化学试剂》;19861231;第8卷(第02期);第94-98页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103601666A (en) | 2014-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103601666B (en) | The preparation method of octahydro pentamethylene [C] pyrroles | |
| CN103113240B (en) | Process for directly synthesizing p-aminophenol through hydrogenation of nitrobenzene | |
| CN102659919A (en) | Synthetic method of bortezomib | |
| CN103467341B (en) | Preparation method for 2-cyano-4'-methylbiphenyl | |
| CN105541714A (en) | Preparation methods of papaverine and papaverine hydrochloride | |
| CN104086392A (en) | Catalytic synthesis method for biphenylacetic acid | |
| CN106892826B (en) | A kind of preparation method and application of amine and imine nitrogen methylation | |
| CN103804234B (en) | The synthetic method of Alpha-Methyl-(3,4-Dimethoxyphenyl)-alpha-amino group propionitrile | |
| CN105218502B (en) | asymmetric synthesis method of chiral chroman compound | |
| CN105859761A (en) | Synthesis method of aromatic borate compounds | |
| CN103739545B (en) | A kind of convenient preparation method of vitamin B6 | |
| CN106117204B (en) | The preparation method of the carboxylic acid of Lei Dipawei intermediates (1R, 3S, 4S) 2 Boc 2 azabicyclo [2.2.1] pentane 3 | |
| CN103113254A (en) | Technology for directly synthesizing acetaminophen from nitrobenzene | |
| CN104788482B (en) | A method for preparing 2-aminopyrimidine-5-boronic acid pinacol ester | |
| CN101812020A (en) | Synthesis method of tetra-substituted imidazole medicament molecule and analogs thereof | |
| CN101538211A (en) | Method for preparing m-aminophenol by catalytic hydrolysis of m-phenylenediamine | |
| CN102617475A (en) | Method for decarboxylation of N-methyl-3-alkyl-4 -nitropyrazole formate | |
| CN118184540B (en) | Preparation method of 2-fluoro-5-formylbenzonitrile | |
| CN102796062B (en) | Method for preparing flumorph | |
| CN104788370B (en) | A kind of method that configuration controllably synthesizes 2 (4 nitro) bytyry N-oxide compounds | |
| CN105315288B (en) | It is a kind of to prepare nafoxidine and the method for pyrazine and isoindole derivatives | |
| CN110511147B (en) | A kind of reduction method of nitroalkene | |
| CN102757376A (en) | Preparation method of b-heterocyclic ketone compound | |
| CN106749041A (en) | A kind of method of synthesizing cytimidine | |
| CN106977488B (en) | A kind of preparation method of 6H- benzo [C] chromene and its derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150902 Termination date: 20201128 |